ALIM News and Press, Alimera Sciences Inc. From 05/09/22

Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 U.S. Net Revenue Increased 23% vs. First Quarter of 2021 U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc....

ATLANTA, May 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will ...

ATLANTA, April 28, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announ...

Shares of Alimera Sciences Inc. (NASDAQ:ALIM) traded at a new 52-week high today of $13.50. Approximately 28.5 million shares have changed hands today, as compared to an average 30-day volume of 33,000 shares. Alimera Sciences Inc. (NASDAQ:ALIM) defies analysts with a current price ($6.0...

ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced ...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

ATLANTA, March 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces t...

Alimera Sciences, Inc (ALIM) Q4 2021 Earnings Conference Call February 24, 2022, 9:00 AM ET Company Participants Scott Gordon – CORE IR Richard Eiswirth – President, CEO & Director Philip Jones – CFO Conference Call Participants Alexander Nowak – Craig-Hallum Y...

Alimera Sciences press release (NASDAQ:ALIM): Q4 GAAP EPS of -$0.59 misses by $0.17. Revenue of $13.95M (+1.3% Y/Y) beats by $0.55M. For further details see: Alimera Sciences GAAP EPS of -$0.59 misses by $0.17, revenue of $13.95M beats by $0.55M

Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 Full Year 2021 Highlights: Consolidated Net Revenue of $59 Million Up 16% vs 2020 Consolidated Net ...